IFNG and colitis: In recombination-activating gene 2 (Rag2)-deficient mice treated with α-CD40 antibodies (Abs) to elicit colitis, the release of IL-23 by myeloid cells activates colonic ILC3s to switch to pro-inflammatory IFN-γ production, thereby promoting the disease13,15,16,18.